SCHULZE GAIL
SEC CIK 1023259 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| CERS | CERUS CORP | Dir | 163.4K | $20.0K | $188.5K | 8 | 2021-11-09 | 2024-06-05 |
Most active insiders at CERS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Greenman William Mariner | Pres, CEO, Dir | — | $1.20M |
| 2 | Benjamin Richard J | Chief Medical Off | — | $670.6K |
| 3 | Jayaraman Vivek K | COO | — | $620.1K |
| 4 | Green Kevin Dennis | CFO | — | $480.5K |
| 5 | Jensen Chrystal | CLO | — | $316.6K |
| 6 | BJERKHOLT ERIC | Dir | — | $53.2K |
| 7 | Gregory Dean A. | Dir | — | — |
| 8 | Shan Hua | Dir | — | — |
| 9 | Lucena Ann | Dir | — | — |
| 10 | Witney Frank | Dir | — | — |
SCHULZE GAIL made no open-market trades at CERS in the last 12 months.
Transactions 8
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-06 | 2024-06-05 | CERS | CERUS CORP | SCHULZE GAIL | Dir | A - Grant | $5.00 | +40.0K | 163.4K | +32% | +$200.0K | |
| 2023-06-09 | 2023-06-07 | CERS | CERUS CORP | SCHULZE GAIL | Dir | A - Grant | $5.00 | +40.0K | 123.4K | +48% | +$200.0K | |
| 2023-05-24 | 2023-05-24 | CERS | CERUS CORP | SCHULZE GAIL | Dir | P - Purchase | $2.03 | +9,850 | 83.4K | +13% | +$20.0K | |
| DA | 2023-01-03 | 2022-12-28 | CERS | CERUS CORP | SCHULZE GAIL | Dir | M - OptEx | $3.19 | +25.0K | 73.6K | +51% | +$79.8K |
| D | 2022-12-30 | 2021-12-28 | CERS | CERUS CORP | SCHULZE GAIL | Dir | M - OptEx | $3.19 | +25.0K | 73.6K | +51% | +$79.8K |
| D | 2022-06-03 | 2022-06-01 | CERS | CERUS CORP | SCHULZE GAIL | Dir | A - Grant | $0.00 | +20.5K | 48.6K | +73% | $0 |
| D | 2021-11-09 | 2021-11-09 | CERS | CERUS CORP | SCHULZE GAIL | Dir | M - OptEx | $2.86 | +25.0K | 53.1K | +89% | +$71.5K |
| D | 2021-11-09 | 2021-11-09 | CERS | CERUS CORP | SCHULZE GAIL | Dir | S - Sale+OE | $7.54 | -25.0K | 28.1K | -47% | -$188.5K |
Purchase Sale Sale after option exercise All abbreviations